• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

TELAPREVIR Drug Record

  • Summary
  • Interactions
  • Claims
  • TELAPREVIR chembl:CHEMBL231813 Approved

    Alternate Names:

    INCIVEK
    MP-424
    VRT-111950
    LY-570310
    LY 570310
    INCIVO
    MP 424
    TELAPREVIR
    VRT 111950
    VX 950
    VX-950
    (1S,3AR,6AS)-(2S)-2-CYCLOHEXYL-N-(PYRAZINYLCARBONYL)GLYCYL-3-METHYL-L-VALYL-N-((1S)-1-((CYCLOPROPYLAMINO)OXOACETYL)BUTYL)OCTAHYDROCYCLOPENTA(C)PYRROLE-1-CARBOXAMIDE
    drugbank:05521
    rxcui:1102261
    chembl:CHEMBL231813
    pubchem.compound:3010818
    chemidplus:402957-28-2

    Drug Info:

    (0 More Sources)

    Publications:

    Fujino H et al., 2014, Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C., J Gastroenterol
    Tsubota A et al., 2014, Impact of IL28B polymorphisms on 24-week telaprevir-based combination therapy for Asian chronic hepatitis C patients with hepatitis C virus genotype 1b., J Gastroenterol Hepatol
    Muir AJ et al., 2014, Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens., Clin Pharmacol Ther
    Pol S et al., 2013, Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure., J Hepatol
    Suzuki F et al., 2011, Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir., Hepatology
    Akuta N et al., 2010, Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin., Hepatology
    Cusato J et al., 2015, Intracellular and Plasma Trough Concentration and Pharmacogenetics of Telaprevir., J Pharm Pharm Sci
  • TELAPREVIR   CYP24A1

    Interaction Score: 7.73

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26158282


    Sources:
    PharmGKB

  • TELAPREVIR   IFNL3

    Interaction Score: 7.27

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24362944 24117654 24096968 23321318 21246582 20648473


    Sources:
    PharmGKB FDA

  • TELAPREVIR   IFNL4

    Interaction Score: 7.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24117654 23321318 21246582 20648473


    Sources:
    PharmGKB

  • TELAPREVIR   CYP3A4

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • PharmGKB: telaprevir

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Akuta N et al., 2010, Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin., Hepatology
    Tsubota A et al., 2014, Impact of IL28B polymorphisms on 24-week telaprevir-based combination therapy for Asian chronic hepatitis C patients with hepatitis C virus genotype 1b., J Gastroenterol Hepatol
    Pol S et al., 2013, Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure., J Hepatol

  • TTD: Telaprevir

    • Version: 2020.06.01

    Alternate Names:
    D0X9CH TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL231813

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Telaprevir

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21